Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma

Journal of Surgical Oncology

Volumn 105, Issue 1, 2012, Pages 15-20

  Berger, Adam C ^a   Fierro, Michael ^a   Kairys, John C ^a   Berd, David ^a   Sato, Takami ^a   Andrel, Jocelyn ^b   Hyslop, Terry ^b   Mastrangelo, Michael J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Lymph node dissection; Lymph node ratio; Melanoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; MALE; MELANOMA; ONCOLOGICAL PARAMETERS; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; ULCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 83455164849     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22051     Document Type: Article

References (14)

1. Geller AC, Miller DR, Annas GD, et al.: Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002; 288: 1719-1720.
2. Balch CM, Soong SJ, Gershenwald JE, et al.: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634. (Pubitemid 32786275)
3. Calabro A, Singletary SE, Balch CM,: Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989; 124: 1051-1055. (Pubitemid 19231243)
4. Morton DL, Wanek L, Nizze JA, et al.: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991; 214: 491-499.
5. Rossi CR, Mocellin S, Pasquali S, et al.: N-ratio: A novel independent prognostic factor for patients with stage-III cutaneous melanoma. Ann Surg Oncol 2008; 15: 310-315.
6. Xing Y, Badgwell BD, Ross MI, et al.: Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 2009; 115: 2505-2513.
7. Inoue K, Nakane Y, Iiyama H, et al.: The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002; 9: 27-34. (Pubitemid 34262894)
8. Sierra A, Regueira FM, Hernandez-Lizoain JL, et al.: Role of the extended lymphadenectomy in gastric cancer surgery: Experience in a single institution. Ann Surg Oncol 2003; 10: 219-226. (Pubitemid 40486953)
9. Bhatti I, Peacock O, Awan AK, et al.: Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma. World J Surg 2010; 34: 768-775.
10. Spillane AJ, Chenug BLH, Winstanley J, et al.: Lymph note ratio provides prognostic information in addition to American Joint Committee on Cancer N stage in patients with melanoma, even if quality surgery is standardized. Ann Surg 2011; 253: 109-115.
11. Balch CM, Buzaid AC, Soong SJ, et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648. (Pubitemid 32786276)
12. Akaike H,: A new look at the statistical model identification. IEEE Trans Automatic Control 1974; 19: 716-723.
13. McMasters KM, Ross MI, Reintgen DS, et al.: Final results of the Sunbelt Melanoma Trial. J Clin Oncol 2008; 16: 2008 (May 20 suppl:abstr 9003).
14. Berd D, Mastrangelo MJ, Sato T,: Calculation of survival of patients with stage III melanoma. J Clin Oncol 2005; 23: 9427.